Cited 0 times in
Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, K | - |
dc.contributor.author | Ko, DH | - |
dc.contributor.author | Jang, JY | - |
dc.contributor.author | Kim, YR | - |
dc.contributor.author | Heo, JY | - |
dc.contributor.author | Kim, YS | - |
dc.date.accessioned | 2024-02-13T23:27:01Z | - |
dc.date.available | 2024-02-13T23:27:01Z | - |
dc.date.issued | 2024 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/32181 | - |
dc.language.iso | en | - |
dc.subject.MESH | CD8-Positive T-Lymphocytes | - |
dc.subject.MESH | COVID-19 | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunotherapy | - |
dc.subject.MESH | Neoplasms | - |
dc.subject.MESH | SARS-CoV-2 | - |
dc.title | Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy | - |
dc.type | Article | - |
dc.identifier.pmid | 37856250 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794008 | - |
dc.contributor.affiliatedAuthor | Jung, K | - |
dc.contributor.affiliatedAuthor | Kim, YR | - |
dc.contributor.affiliatedAuthor | Heo, JY | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1002/cac2.12497 | - |
dc.citation.title | Cancer communications (London, England) | - |
dc.citation.volume | 44 | - |
dc.citation.number | 1 | - |
dc.citation.date | 2024 | - |
dc.citation.startPage | 173 | - |
dc.citation.endPage | 177 | - |
dc.identifier.bibliographicCitation | Cancer communications (London, England), 44(1). : 173-177, 2024 | - |
dc.identifier.eissn | 2523-3548 | - |
dc.relation.journalid | J025233548 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.